

Index

- abdominal compartment syndrome, 7
 abdominal masses. *See also*
 neuroblastoma
 anesthetic strategies for, 110
 differential diagnosis for, 108
 Wilms tumor, 108
 abdominal pain, 254–5
 abdominal wall closure. *See* primary
 abdominal wall closure; staged
 abdominal wall closure
 abdominal walls. *See* anterior
 abdominal wall; posterior
 abdominal wall; truncal blocks
 ABO compatibility, 41
 accidental suffocation, 76
 acetaminophen, 206, 258
 acid base disturbance, with ESRD, 129
 acquired subglottic stenosis, 144
 ACS. *See* American College of Surgeons
 activated protein C, 43
 acute pain management. *See* post-
 operative pain management
 acute respiratory distress syndrome
 (ARDS), 54
 ventilator strategy for, 54
 adductor canal block, 231–2
 femoral block compared to, 231
 with ultrasound, 231–2
 adenoidectomy, 138
 complications after, 139–40
 anxiety as, 140
 with breathing, 140
 postoperative tonsillar bleeding,
 140
 indications for, 137–8
 postoperative plans, 139–40
 length of hospitalization, 139
 adverse muscular or metabolic reaction
 to anesthesia (AMRA),
 66–7
 AEDs. *See* anti-epilepsy drugs
 AIR. *See* Anesthesia-Induced
 Rhabdomyolysis
 airway management
 with anterior mediastinal masses,
 89–90
 rigid bronchoscopy and, 90
 with cleft lip and palate surgery,
 170
 with muscular dystrophy,
 abnormalities with, 65
 cough clearance, 65
 obstructive sleep apnea, 65
 with pediatric burns, 72
 post-intubation complications, 72
 tracheal intubation, 72
 with pediatric trauma, assessment
 strategies, 78
 components of, 78
 in primary survey approach,
 76–7
 before strabismus surgery, 181
 allergy triad, 153
 alveolar concentration of anesthetic
 agents, minimums of, 2–3
 amblyopia, clinical definition, 180
 American College of Surgeons (ACS),
 76
 American Society of Anesthesiologists
 (ASA) standards, 33
 aminocaproic acid, 44
 AMRA. *See* adverse muscular or
 metabolic reaction to anesthesia
 analgesics, 3
 patient-controlled, 5
 anemia, with ESRD, 128–9
 anesthesia. *See* pediatric anesthesia;
 specific illnesses
 Anesthesia-Induced Rhabdomyolysis
 (AIR), 67
 ankle block, 233–4
 dosing regimens, 234
 anterior abdominal wall, 236–8.
 See also truncal blocks
 anatomy of, 237
 boundaries of, 236
 innervation of, 236
 muscles of, 236
 rectus sheath, 236
 thoracolumbar fascia, 236–7
 anterior mediastinal masses
 airway assessment for intubation,
 89–90
 rigid bronchoscopy and, 90
 anesthetic risks, 87
 differential diagnosis of, 86
 ECMO, 90
 lymph node biopsy for, 90
 neuromuscular blocking agents, 89
 intrathoracic pressure with, 89
 ventilation techniques, 89–90
 preoperative diagnostic studies,
 87–9
 AP chest radiographs, 88
 CT scans, 88
 ECG findings, 88
 MMR calculations, 88
 tracheal cross-sectional area, 88
 sedation strategies, precautionary
 plans in, 90
 with SVC syndrome, 89
 symptoms of, 86–7
 airway and respiratory, 86
 cardiovascular, 87
 constitutional, 87
 TLS, 91
 antibiotics, 4
 anticholinergics, for asthma, 47
 anticonvulsive agents, 258
 antiemetics, 11
 anti-epilepsy drugs (AEDs), 161
 antifibrinolytics, 44
 anxiety. *See also* preoperative anxiety
 after adenoidectomy, 140
 separation, 19
 after tonsillectomy, 140
 Apert syndrome, 173–7
 apnea. *See also* neonatal apnea;
 obstructive sleep apnea
 inguinal hernia and, 82
 postoperative probability with,
 82
 in premature infants, apnea of
 maturity, 28
 aPTT coagulation studies, 42
 ARDS. *See* acute respiratory distress
 syndrome
 Arnold-Chiari malformations, 153
 arterial line placement, 34–6
 for blood pressure, 34
 for central venous catheters, 35
 palpation, 34
 for pulmonary artery catheters, 36
 for umbilical catheters, 34
 arterial switch operation, 301
 arterial to end-tidal carbon dioxide
 gradient, 36

- ASA standards. *See* American Society of Anesthesiologists standards
- Ashner, Bernard, 181
- asphyxia, from pediatric burns, 72
- asthma
- bronchodilators and, 48
 - chronic consequences of, 47
 - clinical symptoms, 47
 - differential diagnoses for, 46
 - elective surgery for, delays of, 48
 - emergence management in, 49
 - extubation management, 49
 - inhalation induction in, 48
 - intraoperative bronchospasm management, 49
 - intravenous induction in, 48
 - pathophysiology of, 46–7
 - pharmacological treatments, 47
 - anticholinergics, 47
 - Beta₂-adrenergic agonists, 47
 - corticosteroids, 47
 - cromolyn sodium, 47
 - leukotriene inhibitors, 47
 - methylxanthines, 47
 - NSAIDs, 49
 - pre-anesthetic assessment, 47–8
 - precipitating factors, 46–7
 - premedications for, 48
 - preoperative testing, 48
 - with chest radiographs, 48
 - lab testing, 48
 - for pulmonary functioning, 48
 - prevalence rates for, 46
 - ventilator settings for, 48–9
- atrial septal defects (ASDs)
- age of presentation, 277
 - anesthetic considerations for, 280–1
 - catheter-based repair, 280–1
 - characteristic murmur with, 279–80
 - coronary sinus, 278–80
 - LSVC, 279
 - formation of, 277
 - incidence rates, 277
 - pathophysiology of, 279
 - primum, 278–9
 - secundum, 277–8, 280
 - sinus venosus, 278, 280
 - surgical approaches to, 280–1
 - types of, 277–8
 - unrepaired, 279
 - natural history of, 280
- atrial septum, 296
- atrioventricular canal (AVC) defect, 286
- cardiac catheterization and, 286
 - clinical presentation of, 286
 - natural history of, 286
 - pulmonary hypertension, 286
 - Rastelli classifications for, 286
 - types of, 286–7
- atrophy. *See also* spinal muscular atrophy
- juvenile spinal muscular, 68
 - from muscular dystrophy, 64
- AVC defect. *See* atrioventricular canal defect
- axillary nerve block, 223
- ultrasound imaging, 222–3
- balloon trial septostomy, 298
- Becker muscular dystrophy (BMD), 67
- Beckwith-Wiedemann syndrome, 9–10, 111
- anesthetic work-up, 9
 - with D10 as maintenance fluid, 10
 - elevated hematocrits, 10
 - associated malformations, 9
 - cardiac anomalies, 9
 - embryonal tumors, 9
 - renal anomalies, 9
 - Crigler-Najjar syndrome, 10
 - hemihypertrophy and, 9
 - hyperbilirubinemia, 10
 - jaundice risks, 10
 - macroglossia and, 9
 - neonatal hypoglycemia risks, 9–10
 - phenotypic appearance of, 9
 - visible icterus and, evaluation of, 10
- benzodiazepines, 75, 183, 248
- Beta₂-adrenergic agonists, 47
- biliary atresia, 118
- associated pathophysiological issues, 118
 - natural history, 118
- bladder exstrophy
- anomalies associated with, 189
 - clinical features of, 189–90
 - intraoperative management, 191
 - fluid management, 191
 - monitoring as part of, 191
 - pain management, 191
 - metabolic derangements, 190–1
 - pain management
 - intraoperative, 191
 - postoperative, 191–2
 - preoperative evaluation for, 190–1
 - severity of, 189
 - treatment options for, 189–90
- bleeding disorders
- hemophilia and, 39–40
 - thalassemia and, 38
 - vWD, 38–9
- bleomycin, 109
- blood donation. *See* preoperative autologous blood donation
- blood loss
- from burn debridement, 74
 - blood transfusion indications, 74
- with IS, 204
- with NMS, 204
- blood pressure
- monitoring of
 - arterial line placement for, 34
 - of normal blood pressure levels, 34
 - values, for children, 1
- blood products, 2–4
- blood recovery, 44
- blood reinfusion, 44
- blood transfusions. *See* transfusions
- blood volume
- estimates for transfusions, 40
 - values, for children, 1–2
- BMD. *See* Becker muscular dystrophy
- body surface area (BSA), for premature infants, 30
- BPD. *See* bronchopulmonary dysplasia
- bradycardia
- CSF shunts and, 156
 - after liver transplantation, 126–7
- bronchodilators, 48
- bronchopulmonary dysplasia (BPD), 28–9
- bronchopulmonary sequestration, 106
- bronchoscopy
- for EA/TEF, 94
 - rigid, 90
- BSA. *See* body surface area
- bupivacaine, 192, 215
- burns, pediatric
- airway management, 72
 - post-intubation complications, 72
 - tracheal intubation, 72
 - anesthetic management, 71–2
 - with neck and chest burns, 72
 - pharmacological implications in, 73
 - succinylcholine and, 73
- asphyxia from, 72
- blood loss and, from burn
- debridement, 74
 - blood transfusion indications, 74
- causes of, 70
- chemical, 70
- classifications of, 70–1
- through BSA, 71
 - fourth degree burns, 71
 - full thickness burns, 70–1
 - partial thickness burns, 70–1
 - superficial burns, 70
- from cold exposure, 70
- from electric currents, 70
- fluid management with, 73
- inhalation, 70
- carbon monoxide toxicity, 72
 - cyanide toxicity, 72–3
 - monitoring considerations, 74
 - morbidity risks with, 71

- burns, pediatric (cont.)
 - mortality risks with, 71
 - organ system changes, 74–5
 - hypermetabolic responses, 74–5
 - pain management strategies, 75
 - analgesic options, 75
 - sedative options, 75
 - radiation, 70
 - respiratory failure from, 72
 - temperature management with, 73
 - thermal, 70
- caffeine, as stimulant, 82
- caffeine-halothane contracture test (CHCT), 57
- carbon monoxide toxicity, 72
- cardiac anomalies, with Beckwith-Wiedemann syndrome, 9
- cardiac catheterization. *See also* atrioventricular canal defect
 - after congenital heart surgery, 289
 - with Down syndrome, 289
 - hemodynamic data for, 287–8
 - oxygen saturation, 288
 - pulmonary obstruction and, 289
 - pulmonary vascular resistance, calculations for, 289
 - Qp:Qs ratio and, 288–9
 - for VSD, 284
- cardiac disease, muscular dystrophy and, 64–5
- cardiopulmonary bypass, 300
- cardiovascular drugs, dosing of, 4–5
- caudal blocks, for circumcision, 184–7
 - adjunct medications for, 186–7
 - confirmatory tests for, 186
 - contraindications to, 185
 - epinephrine test dose, 185
 - local anesthetic dosing in, 186
 - performance of, 185
 - peripheral nerve blocks compared to, 187–8
 - sacral dimples and, 185–6
 - safety record for, 187
 - ultrasound for, 186
- caudal epidural, for inguinal hernia, 84
- caudal epidural space, anatomy of, 184
- CBF. *See* cerebral blood flow
- CDH. *See* congenital diaphragmatic hernia
- cell saver, 44
- central venous catheters, 35
- cerebral blood flow (CBF), 167
- cerebral metabolic rate, 167
- cerebral palsy, in premature infants, 29–30
 - classification of, 30
 - consequences of, 30
 - incidence rates of, 30
- cerebral salt wasting syndrome, 159–60
- cerebral spinal fluid (CSF), 155–6
 - production to reabsorption pathway, 155–6
 - shunts and, 155–6
 - bradycardia and, 156
 - malfunction of, 156
 - placement of, 155
- cerebral steal, 167–8
- cervical spine injury, anesthetic implications with, 79
- CFTR gene. *See* Cystic Fibrosis Transmembrane Regulator gene
- CH. *See* congenital hypothyroidism
- CHARGE syndrome, 144
- CHCT. *See* caffeine-halothane contracture test
- chemical burns, 70
- chemoreceptor trigger zone (CTZ), 24
- child life specialists, 260–1
- chloroprocaine, 215
- chondrodysplastic myotonia, 65
- chronic kidney disease (CKD), 128
- chronic opioid therapy (COT), 258
- chronic pain. *See also* distraction techniques
 - from abdominal pain, 254–5
 - COT, 258
 - from headaches, 254–5
 - IASP guidelines, 254–5
 - intraoperative adjunct therapy for, 258
 - pain catastrophizing, 256–7
 - parental catastrophizing, 257
 - in perioperative period, 255–6
 - p-FA model, 257
 - in postoperative settings, 254
 - preoperative chronic opioid use, 254
 - prevalence of, 254
 - psychosocial model, 257
- chronic postsurgical pain (CPSP), 256–7
 - prevention strategies for, 258
 - regional anesthesia for, 257–8
 - risk factors for, 256
- circulation. *See* fetal circulation; transitional circulation
- CKD. *See* chronic kidney disease
- CLE. *See* congenital lobar emphysema
- cleft lip and palate
 - anesthetic considerations, 171
 - classification of, 169
 - common associated craniofacial syndromes, 170
 - development of, 169
 - incidence rates for, 169
 - intraoperative considerations, 171
- analgesia plans, 171
- extubation plans, 171
- nerve blocks, 171
- physiological issues with, 169
- postoperative preparations, 171
- predisposing risk factors, 169
- preoperative considerations, 170
 - airway examinations, 170
 - premedication assessment, 170
- repair procedures for, 169–70
 - Eustachian tube function, 170
 - orthodontic interventions, 170
- VPI, 170
- clonidine, 22, 186–7, 250
- clotting factors, 41
- coarctation of the aorta
 - anesthetic considerations, 275
 - clinical definition, 273–4
 - CT scan of, 275
 - diagnosis of, 274
 - differential cyanosis, 273–4
 - hemodynamic consequences of, 273
 - prostaglandin E1 administration, 274
 - re-coarctation, 275–6
 - surgical repair of, 274–5
 - common side effects of, 275
 - complications from, 275
 - Turner syndrome, 273
 - cardiac issues with, 273
- Cobb angle, 202–3
- cold exposure, burns from, 70
- complex craniosynostosis, 173
- component therapy, 41
- computed tomography (CT) scans
 - for anterior mediastinal masses, 88
 - coarctation of the aorta, 275
 - for hydrocephalus, 155–6
- congenital diaphragmatic hernia (CDH)
 - clinical definition, 100
 - diagnosis of, 100–1
 - differential, 100
 - ECMO, 102
 - fetal delivery strategies with, 101
 - long-term complications, 102
 - pathophysiology of, 100
 - prenatal interventions, 101
 - EXIT, 101
 - prognosis for, 100–1
 - with LHR, 100–1
 - morbidity rates, 101
 - mortality rates, 101
 - with PPLV, 101
 - pulmonary hypertension management, 102
 - surgical repair for, 102
 - ventilator management options, 101–2
 - gentle, 102

- congenital heart defects, 307
 congenital heart disease, 252–3
 congenital heart surgery, 289
 congenital hyperinsulinism, 113–17.
 See also hypoglycemia
 age of presentation, 114
 anesthetic considerations, 116
 clinical definition, 113
 clinical presentation, 114
 diagnosis of, 114–15
 diffuse, 113–14
 focal, 113–14
 genetic components of, 113
 incidence rates for, 114
 management of, 114–16
 failures in, 114–15
 through first-line treatments, 114
 surgical, 114–16
 postoperative care, 116–17
 glucose management in, 116
 outcomes of, 117
 congenital hypothyroidism (CH), in neonates, 13–14
 incidence rates for, 13
 screening programs for, 13–14
 congenital lobar emphysema (CLE), 106
 congenital lung malformations, 11
 bronchopulmonary sequestration, 106
 CLE, 106
 CPAM, 106
 congenital pulmonary airway malformation (CPAM), 106
 congenital subglottic stenosis, 144
 conotruncal VSD, 284
 consent. *See* informed consent
 continuous gastric insufflation, 95
 controlled hypotension, 44, 204–5
 coronary sinus ASDs, 278–80
 LSVC, 279
 corticosteroids, for asthma, 47
 COT. *See* chronic opioid therapy
 cough clearance, 65
 coventricular VSD, 284
 CPAM. *See* congenital pulmonary airway malformation
 CPSP. *See* chronic postsurgical pain
 cranial suture closure, 173–4
 natural progression of, 173–4
 cranial vault reconstruction, 174–5
 craniosynostosis
 Apert syndrome, 173–7
 associated syndromes, 173
 blood transfusions, 176–7
 platelet ratios, 176–7
 reduction strategies, 177
 clinical definition, 173
 complex, 173
 cranial suture closure, 173–4
 natural progression of, 173–4
 cranial vault reconstruction, 174–5
 Crouzon syndrome, 174–7
 endoscopic strip craniectomy, 175
 incidence rates, 173
 intraoperative management, 175–6
 anesthetic issues, 176
 bleeding risks, 176
 blood transfusions, 176
 surgical risks, 175
 VAE risk factors, 176
 postoperative management, 177
 electrolyte abnormalities, 177
 surgical complications, 177
 preoperative testing, 175
 Saethre-Chotzen syndrome, 174–7
 simple, 173–7
 spring-assisted cranioplasty, 175
 Cravero scale, for ED, 27
 cricoid cartilage, 145
 Crigler-Najjar syndrome, 10
 cromolyn sodium, 47
 Crouzon syndrome, 174–7
 cryoprecipitate indications, 41
 CSF. *See* cerebral spinal fluid
 CT scans. *See* computed tomography scans
 CTZ. *See* chemoreceptor trigger zone
 Cushing, Harvey, 156
 Cushing's reflex, 156
 cyanide toxicity, 72–3
 cystic fibrosis
 anesthetic maintenance strategies, 62
 CFTR gene and, 60
 extra-operative issues with, 62
 extubation with, 62
 non-pulmonary manifestations of, 60–1
 paralysis and, 62
 postoperative mechanical ventilation with, risk factors for, 62
 preoperative assessment with, 60–2
 anesthesia induction in, 61–2
 premedication indications, 61
 studies in, 60–1
 pulmonary manifestations of, 60–1
 sugammadex therapy, 62
 tobramycin therapy, 62
 Cystic Fibrosis Transmembrane Regulator (CFTR) gene, 60
 D10, as maintenance fluid, 10
 Dagnini, Giuseppe, 181
 deceased donor kidney transplant (DDKT), 130
 dental procedures, anesthesia for
 criteria for, 178
 endocarditis prophylaxis, antibiotics for, 179
 nasal intubation, 179
 tracheal intubation types, 178–9
 dexamethasone, 182–3
 dexmedetomidine, 20, 147, 205, 250
 diabetes insipidus, 159–60
 diazepam, 22, 206
 diazoxide, 114
 diffuse congenital hyperinsulinism, 113–14
 disseminated intravascular coagulation, 54
 distraction techniques, 260–2
 application of, 260–1
 categorizations for, 261–2
 child life specialists and, 260–1
 for children and adolescents, 261
 distinctions between, 261–2
 implementation of, 262
 barriers to, 262
 selection of, 262
 distraction therapy, 75
 DMD. *See* Duchenne muscular dystrophy
 dopamine, 133
 Down syndrome, 144, 289
 doxorubicin, 109
 D-TGA, 296
 arterial blood gas in, 297–8
 Duchenne muscular dystrophy (DMD), 66–7
 preoperative cardiac considerations, 66–7
 volatile anesthetic use, 67
 ductus arteriosus, 269. *See also* patent ductus arteriosus
 with dependent lesions, 270
 intravenous prostaglandins and, risks of, 270
 spontaneous closure of, 270
 dysfunctional pain, 249–50
 EA. *See* esophageal atresia
 ear tube placement. *See* myringotomy
 echocardiogram (ECG) findings
 for anterior mediastinal masses, 88
 in Glenn procedures, 330
 intraoperative transesophageal echocardiography, 300
 for TGA, 298
 ECMO. *See* extracorporeal membrane oxygenation
 ECOG. *See* electrocorticography
 ED. *See* emergence delirium
 electric burns, 70

- electrocardiogram, 330
 electrocorticography (ECOG), 162–3
 electrolyte abnormalities, 128–9
 with craniosynostosis, 177
 elevated hematocrits, 10
 embryonal tumors, 9
 emergence delirium (ED)
 clinical definition of, 26
 incidence rates, 26
 long-term sequelae of, 26
 measurement of, 26
 Cravero scale, 27
 PAED scale, 27
 Watcha scale, 27
 risk factors for, 26
 after strabismus surgery, 183
 treatment strategies, 26
 endocarditis prophylaxis, 179, 271–2
 endoscopic strip craniectomy, 175
 endotracheal tube (ETT) positioning,
 with EA/TEF, 94
 end-stage liver disease, 119–20, 122
 circulatory systems with, 119–20
 coagulation issues, 120
 gastrointestinal systems with, 120
 pathophysiologic derangements of,
 122–3
 PELD score, 122
 PPHN and, 120
 end-stage renal disease (ESRD), 128–9
 acid base disturbance, 129
 anemia with, 128–9
 clinical manifestations of, 129
 diagnoses for transplantation, 129
 electrolyte abnormalities with, 128–9
 incidence rates, 129
 organ systems with, 128
 treatment options, 129
 epidural catheters, pediatric
 in awake patients, 214
 common local anesthetic solutions,
 215
 contraindications to, 215
 depth of epidural space, 214
 in neonates compared to adults,
 214–15
 placement of, 214
 in sleeping patients, 214
 solution additives in, 215
 test dosing of, 214
 epilepsy
 HH and, 161
 ketogenic diet, 161
 laser ablation, 161–2
 ECOG techniques, 162–3
 intra-operative monitoring, 162
 postoperative considerations, 162–3
 pre-surgery transport, 162
 MRI for, 162
 seizures and, incidence rates for, 161
 treatment options for, 161
 with AEDs, 161
 vagal nerve stimulator, 161
 epinephrine test doses, 185
 epinephrine treatment, 52
 equipment sizes, for children, 2
 erector spinae block, 243
 erythromycin, 21
 erythropoietin, 44
 esophageal atresia (EA), 92. *See also*
 VACTERL/VATER syndrome
 age of presentation, 92
 bronchoscopy for, 94
 cardiac defects with, 93
 continuous gastric insufflation, 95
 ETT positioning, 94
 fistula variants, 92–3
 head and neck maneuvers after, 95
 incidence rates, 92
 induction methods for, 94
 intraoperative approach to, 95
 mortality expectations with, 94
 postoperative approach to, 95
 preoperative evaluations with, 94
 regional anesthetics for, 95
 esotropia, 180
 ESRD. *See* end-stage renal disease
 Eustachian tube function, 170
 evoked potentials, 154
 anesthetics with, 154
 EXIT. *See* Ex-Utero Intrapartum
 Treatment
 exotropia, 180
 extracorporeal membrane oxygenation
 (ECMO), 90, 102
 VAD compared to, 320–1
 Ex-Utero Intrapartum Treatment
 (EXIT), 101
 case study, 195–6
 clinical definition, 193
 common indications for, 193–4
 patient selection for, 193
 postoperative outcomes, 195
 preoperative evaluation for,
 193–5
 anesthetic concerns, 194–5
 fetal concerns, 194–5
 logistical concerns, 194
 maternal concerns, 193–5
 resuscitation issues, 195
 Factor concentrates, 2–4
 fascia iliaca block, 228–30
 imaging of, 231
 FDA. *See* Food and Drug
 Administration
 FDT. *See* forced duction test
 femoral block, 226–8
 adductor canal block compared to,
 231
 imaging of, 230–1
 local dosing options, 228
 fenestrated Fontan procedures, 316
 fentanyl, 147, 186–7, 205
 metabolism of, 13
 fetal circulation, 264–5
 adult circulation compared to, 264–5
 oxygen carrying capacity in,
 265–6
 persistent, 266–7
 SVC, 264
 fetal delivery, with CDH, 101
 FiBTEM, 42–3
 first degree burns. *See* superficial
 burns
 focal congenital hyperinsulinism,
 113–14
 Fontan procedures
 completion surgery, timeframe for,
 315–16
 desaturation of Fontan, 316
 extubation with, 319
 failure of, 317
 preserved systolic function after,
 318
 fenestrated, 316
 hypotension management with,
 318–19
 ideal circulation for, 316–17
 intraoperative monitoring of, 318
 laparoscopic surgery and, 319
 preoperative evaluation of, 318
 protein losing enteropathy, 317
 saturation of Fontan, 316
 types of, 315–16
 by ventricle, 317–18
 Food and Drug Administration (FDA),
 anesthetic neurotoxicity
 warnings by, 16–17
 drug listings in, 16–17
 neuroapoptosis, 16–17
 studies for, 16
 forced duction test (FDT), 181
 foreign body aspirations
 clinical presentation of, 141
 diagnostic radiographs of, 141–2
 physical examinations for, 141
 surgical removal of, 142–3
 anesthetic management
 techniques, 142
 complications after, 143
 complications during, 142
 as emergency, 142
 types of, 141
 fourth degree burns, 71
 full thickness burns, 70–1

- G6PD deficiency. *See* glucose-6-phosphate dehydrogenase deficiency
- gabapentin, 250
- gastroschisis, in neonates, 6–9
 abdominal compartment syndrome and, 7
 anesthetic considerations for, 8
 risks as part of, 8
 RSI in, 8
 characteristics of, 6
 diagnostic evaluations for, 8–9
 laboratory evaluations for, 8–9
 management of, 6
 omphalocele compared to
 characteristic differences in, 6
 pathophysiological differences, 6
 preoperative evaluations for, 8–9
 prevalence rates for, 6
 primary abdominal wall closure, 7–8
 prognosis for, 9
 staged abdominal wall closure, 7–8
- GCS. *See* Glasgow Coma Scale
- general anesthesia, for premature infants, 31
 postoperative apnea from, 31
- Glasgow Coma Scale (GCS), 77
- Glenn, William, 328
- Glenn procedures. *See also* superior cavopulmonary anastomosis; total cavopulmonary anastomosis
 bidirectional, 328–9
 blood flow to heart in, 328
 echocardiogram as part of, 330
 electrocardiogram as part of, 330
 preoperative assessment, 331
 with SBE prophylaxis, 331
 SCPA and, 328
 URIs and, 331
- glucagon, 114
- glucose management, with congenital hyperinsulinism, 116
- glucose-6-phosphate dehydrogenase
 Graves' disease, 149
- Haller index, 208–9
- HAT. *See* hepatic artery thrombosis
- headaches, chronic pain from, 254–5
- heart rate values, for children, 1
- hematemesis, 119
- hematopoietic stem cell
 transplantation, 42
- hemihypertrophy, 9
- hemoglobin-oxygen saturation, 328–9
- hemophilia, 39–40
- heparin resistance, 41
- hepatic artery thrombosis (HAT), 127
 hepatic encephalopathy, 120
 West Haven criteria for, 120
- hepatic portoenterostomy. *See* Kasai procedure
- hepatopulmonary syndrome, 119
- hepatorenal syndrome, 119
- hernia. *See* congenital diaphragmatic hernia; incarcerated inguinal hernia; inguinal hernia
- HH. *See* hypothalamic hamartoma
- HPS. *See* hepatopulmonary syndrome
- hydrocephalus, 155–6
 causes of, 155
 CT scans of, 155–6
 ex-vacuo, 155
- hydroxyethyl starch, in platelet
 function, 41
- hyperbilirubinemia, 10
 kernicterus from, 10–11
 pulse oximetry and, 36
- hypertension
 after neuroblastoma surgery, 109–10
- PPHN, 120
- pulmonary, 286
 with CDH, 102
 in premature infants, 28
- renal transplantation and, 130
- hyperthermia, malignant (MH)
 anesthetic management of, 58–9
 charcoal filters in, 58
 clinical definition of, 57
 diagnosis of, 57
 CHCT in, 57
 diseases associated with, 57–8
 genetic mutations with, 58
 incidence rates, 57
 strabismus and, 181
 treatment for, 58
- hypertropia, 180
- hypnosis, 75
- hypocalcemia, 150
- hypoglycemia, in neonates and infants, 113
 clinical characteristics, 113
 differential diagnosis, 113
 neonatal risks for, 9–10
 in premature infants, 30
- hypotension
 controlled, 44, 204–5
 with Fontan procedures, 318–19
 after liver transplantation, 126–7
 renal transplantation and, 132
- hypothalamic hamartoma (HH), 161
- hypothermia
 MoyaMoya disease and, 167
 pediatric trauma and, 79
 for premature infants, 30
- hypothyroidism
 CH, in neonates, 13–14
 incidence rates for, 13
 screening programs for, 13–14
- maternal, 14
- hypotropia, 180
- hypoxemia, 105
 hepatopulmonary syndrome and, 119
 Kasai procedure and, 119
 with myringotomy and ear tube placement, 134
 with URIs, 134
- IASP. *See* International Association for the Study of Pain
- ICP. *See* raised intracranial pressure
- idiopathic scoliosis (IS), 202
 blood loss with, 204
- ilioinguinal-iliohypogastric block, 238–41
- incarcerated inguinal hernia, 81
- infants. *See* neonates
- inflammatory pain, 249–50
- informed consent, 20
- infraclavicular block
 contraindications for, 220
 indications for, 219–20
 postoperative considerations with, 223
 ultrasound imaging, 220–1
- inguinal hernia, 81–4
 anesthetic methods for, 81–2
 age factors for, 81–2
 with general anesthesia, 81–2
 with regional anesthesia, 81
- apnea and, 82
 postoperative probability for, 82
- caffeine as stimulant with, 82
- caudal epidural, in infants, 84
- clinical definition of, 81
- incarcerated, 81
- spinal anesthesia, in infants, 82–4
 cardiorespiratory effects, 83–4
 patient management in, 83
 preoperative application of, 83
- inhalation burns, 70
 carbon monoxide toxicity, 72
 cyanide toxicity, 72–3
- inlet VSD, 284
- International Association for the Study of Pain (IASP), 254–5
- interscalene brachial plexus nerve
 block, 216–18
 anatomy imaging, 218–19
 complications from, 216–17
 contraindications for, 216
 indications for, 216
 patient positioning, 218
 performance of, 218
 phrenic nerve blocks and, 218

- interscalene brachial plexus nerve block (cont.)
 as postoperative option, 216–17
 side effects of, 216–17
- intraoperative transesophageal echocardiography, 300
- intraosseous lines, 78–9
- intraventricular hemorrhage (IVH), in premature infants, 28–9
 grading of, 29–30
 pathophysiology of, 29
- IS. *See* idiopathic scoliosis
- IVH. *See* intraventricular hemorrhage
- jaundice, with Beckwith-Wiedemann syndrome, 10
- junctional ectopic tachycardia (JET), 294
- juvenile spinal muscular atrophy, 68
- Kasai procedure (hepatic portoenterostomy), 119
 anesthetic implications of, 120–1
 intra-operative considerations, 121
 postoperative considerations, 121
 preoperative considerations, 120–1
 hematemesis, 119
 hypoxemia and, 119
 prognosis for, 119
 timing of, 119
- kernicterus, prevention strategies for, 10–11
- ketamine, 22–3, 147, 187, 205, 250–1
 for chronic pain, 258
 intramuscular, 23
- ketogenic diet, 161
- ketorolac, 206, 258
- kidney reperfusion, 132
- kidneys. *See* renal function
- laparoscopic surgery, 319, 332
- laryngeal mask airway, 332
- laryngeal nerve injuries, 150
- laryngotracheal reconstruction surgery (LRS). *See also* subglottic stenosis
 anesthetic considerations for, 147
 contraindications to, 147
 postoperative considerations, 147–8
 steps in, 147
- laser ablation, 161–2
- ECOG techniques, 162–3
 intra-operative monitoring, 162
 postoperative considerations, 162–3
 pre-surgery transport considerations, 162
- LAST. *See* local anesthetic system toxicity
- lazy eye. *See* amblyopia
- left superior vena cava (LSVC), 279
- leukotriene inhibitors, 47
- LHR. *See* lung-to-head ratio
- lidocaine, 192, 251
- liver failure
 electrolyte abnormalities, 124
 hematologic abnormalities, 124
 medication choice and, 125
 preoperative workup, 123–4
- liver function. *See also specific disorders*
 fetal
 drug metabolism, 11
 protein synthesis in, 11
- liver transplantation
 anesthetic induction with, 125
 anhepatic phase, 125–6
 bradycardia after, 126–7
 diagnoses for, 122
 for end-stage liver disease, 122
 pathophysiologic derangements of, 122–3
 PELD score, 122
 graft failure, etiology of, 127
 HAT, 127
 hypotension after, 126–7
 after liver failure
 electrolyte abnormalities, 124
 hematologic abnormalities, 124
 medication choice and, 125
 preoperative workup, 123–4
 monitors needed for, 124–5
 postoperative considerations, 127
 pre-anhepatic phase, 125
 preoperative workup for, 122–4
 evaluation tests in, 123–4
 for liver failure, 123–4
 MARS therapy, 124
 primary indications for, 122–3
 reperfusion phase, 126
 well-functioning grafts after, 127
- local anesthetic system toxicity (LAST)
 clinical definition, 246
 differential diagnosis, 246
 incidence rates for, 246
 prevention strategies, 247–8
 symptoms, 246–7
 ECG changes, 247
 treatment strategies, 248
- long-term VAD, 321
- lower extremity nerve blocks
 adductor canal block, 231–2
 femoral block compared to, 231
 with ultrasound, 231–2
 ankle block, 233–4
 dosing regimens, 234
- fascia iliaca block, 228–30
 imaging of, 231
- femoral block, 226–8
 adductor canal block compared to, 231
 imaging of, 230–1
 local dosing options, 228
- innervation in, 225
 cutaneous, 227
 regional anesthetic options, 225–6, 230–1
- sacral plexus nerve blocks, 225–8
- sciatic nerve block, 232–3
 imaging of, 232–3
- LSVC. *See* left superior vena cava
- L-TGA, 296
- lumbar plexus nerve blocks, 225–8
 imaging of, 229
 local dosing options, 226
- lung volume and function. *See also*
 pulmonary artery catheters;
 pulmonary hypertension;
 thoracic surgery; *specific disorders*
 with asthma, preoperative testing, 48
- cystic fibrosis and, 60–1
 with ECMO, 90, 102
 in neonates, 11
 pulmonary function, differences with adults, 12
- PPLV, 101
- lung-to-head ratio (LHR), 100–1
- lymph node biopsy, 90
- MAC. *See* minimum alveolar concentration
- macroglossia, 9
- magnetic resonance imaging (MRI)
 for epilepsy, 162
 of myelomeningocele, 153
 for pediatric neurological tumors, 158–60
- malignant hyperthermia. *See* hyperthermia
- Malignant Hyperthermia Association of the United States (MHAUS), 65
- Management of Myelomeningocele Study (MOMS), 198–9
- MARS therapy. *See* molecular adsorbent recirculating system therapy
- masseter muscle spasm, 181
- massive blood transfusion (MBT), 41–2
- maternal hypothyroidism, 14
- MBT. *See* massive blood transfusion
- McGill Oximetry Scoring System, 137–8

- mediastinal mass ratio (MMR)
calculations, 88
- mediastinum, 86. *See also* anterior
mediastinal masses
compartments of, 86–7
- meizothrombin, 43–4
- Melody valve, 295
- methadone, 205
- methylxanthines, 47
- metoclopramide, 182
- MH. *See* hyperthermia
- MHAUS. *See* Malignant Hyperthermia
Association of the United States
- midazolam, 147, 205
catheter administration of, 22
erythromycin and, 21
nasal administration of, 22
plasma, 21
for preoperative anxiety, 20–2
- mid-gestational fetal procedures. *See*
open neural tube defects
- milrinone, 52
- minimum alveolar concentration
(MAC), 13
- MMR calculations. *See* mediastinal
mass ratio calculations
- MODS. *See* multi-organ dysfunction
syndrome
- molecular adsorbent recirculating
system (MARS) therapy, 124
- MOMS. *See* Management of
Myelomeningocele Study
- monitoring, of pediatric patients
arterial line placement, 34–6
for blood pressure, 34
for central venous catheters, 35
palpation, 34
for pulmonary artery catheters, 36
for umbilical catheters, 34
- arterial to end-tidal carbon dioxide
gradient, 36
- ASA standard monitors, 33
- with bladder exstrophy, 191
- blood pressure
arterial line placement, 34
normal levels and, 34
- with burns, 74
- cuff size choice as part of, 33
- with Fontan procedures, 318
- during liver transplantation, 124–5
- for neuromuscular blockades, 36
- with NIRS, 33
pulse oximetry compared to, 33
- pulse oximetry
NIRS compared to, 33
sources of error in, 36
- with renal transplantation, 130–1
- through TEE, 36
- for temperature, 36
- morphine, 186–7
metabolism of, 13
- MoyaMoya disease
age of presentation, 165
anesthetic considerations for, 166–8
for CBF, 167
for cerebral metabolic rate, 167
for hypothermia, 167
- angiographic stages, 165–6
- diagnosis of, 165
- disease stages, 165
- disorders associated with, 164
- epidemiology of, 164
- imaging of, 165
- pathophysiology of, 164
- postoperative considerations, 168
- prognosis factors, 165
- symptoms, 165
- treatment therapies
cerebral steal risks, 167–8
through medical management,
165–6
through surgery, 166–8
- MRI. *See* magnetic resonance imaging
- multi-organ dysfunction syndrome
(MODS), 50, 53–4
sequential organ failure assessment,
53–4
- muscle relaxants, non-polarizing, 66
- muscular dystrophy
AIR, 67
airway abnormalities with, 65
cough clearance, 65
obstructive sleep apnea, 65
- atrophy as result of, 64
- BMD, 67
- cardiac disease and, 64–5
- diagnosis of, 64
muscle biopsy in, 64
testing as part of, 64–5
- DMD, 66–7
preoperative cardiac
considerations, 66–7
volatile anesthetic use, 67
- intraoperative management of,
12
anesthetic options in, 65
non-MH triggering anesthetics in,
65–6
non-polarizing muscle relaxants,
66
succinylcholine in, safety of, 66
temperature management as part
of, 65–6
- postoperative considerations with,
66
- AMRA, 66–7
- hospital discharge considerations,
66
- preoperative evaluation of, 64–5
exam findings in, 64
testing as part of, 64–5
- muscular VSD, 284–5
- myelomeningocele, 152–5
allergy triad with, 153
anesthetic issues with, 154
with evoked potentials, 154
Arnold-Chiari malformations, 153
defects with, 152
etiology of, 152
evoked potentials and, 154
anesthetics with, 154
mid-gestation fetal repair of, 153
MRI of, 153
neurologic disabilities with, 153
neurologic morbidity with, 153
surgical procedures with, 154–5
- Myer-Cotton grading scale, 144–6
- myringotomy, ear tube placement and
anesthetic management plans,
134
with healthy children, 135
with URIs, 134–5
- indications for, 134
- URIs and, 134
anesthetic management with,
134
hypoxemia and, 134
timing of elective procedures,
135–6
- near-infrared spectroscopy (NIRS), 33
- necrotizing enterocolitis (NEC), 31
- neonatal acidosis, 31
- neonatal apnea, 12–13, 84–5
discharge criteria, by gestational age,
84
etiologies of, 12–13, 84
prevalence of, 84
risk factors, 13, 84
treatments for, 13
- neonates. *See also* Beckwith-
Wiedemann syndrome;
gastroschisis; hypoglycemia;
neonatal apnea; omphalocele
- CH and, 13–14
incidence rates for, 13
screening programs for, 13–14
- epidural catheters for, 214–15
- fentanyl metabolism in, 13
- fetal liver
drug metabolism, 11
protein synthesis in, 11
- hematological system, differences in,
11–13
- kernicterus prevention strategies,
10–11
- lung volume in, 12

- neonates (cont.)
 pulmonary function, differences with adults, 12
 MAC and, 13
 maternal hypothyroidism, 14
 morphine metabolism in, 13
 neuromuscular blockade monitoring, 36
 oxygen delivery in, 12
 PDA in, 36
 protein synthesis in, by neonatal liver, 11
 renal function, adult function compared to, 11–12
 respiratory mechanics in, 12
 screening programs, 14
 for CH, 13–14
 spinal anesthetics in, 13
 with TAPVR, 304–5
 long-term outcome of, 305
 short-term outcome of, 304
 TGA in, 297–8
 anesthetic considerations, 299
 palliative procedures for, 299
 surgical options for, 298–9
 nerve blocks, 171. *See also* upper extremity nerve blocks
 phrenic, 218
 supraclavicular brachial plexus block, 218–20
 neural integrity monitoring (NIM) tube, 149–50
 neural tube defects. *See* open neural tube defects
 neuroapoptosis
 in FDA warnings, 16–17
 parental notifications about, 17–18
 neuroblastoma, 108–10
 anesthetic concerns with surgical resection, 109–10
 bleeding issues, 110
 hypertension as, 109–10
 third space fluid loss, 110
 ventilation issues, 110
 chemotherapy drugs, 109
 clinical characteristics, 108
 diagnosis of, 108–9
 epidemiology of, 108–9
 incidence rates, 108–9
 staging systems for, 109
 neurological tumors, pediatric
 common pathologies for, 157–8
 MRI of, 158–60
 optimal PaCO₂, 157–8
 posterior fossa tumor, 158–60
 surgical positioning for, 159
 syndromes associated with, 159–60
 VAE in, 159–60
 types of, 157–8
 neuromuscular blocking
 with anterior mediastinal masses, 89
 intrathoracic pressure, 89
 ventilation techniques, 89–90
 in neonates, 36
 neuromuscular scoliosis (NMS), 202
 blood loss with, 204
 neuropathic pain, 249–50
 neurotoxicity, anesthetic
 as dose-dependent, 16
 FDA warnings, 16–17
 drug listings in, 16–17
 neuroapoptosis, 16–17
 studies for, 16
 human studies on, 16–17
 future studies, 17
 neuroapoptosis
 in FDA warnings, 16–17
 parental notifications about, 17–18
 prevention strategies for, 18
 NIM tube. *See* neural integrity monitoring tube
 NIRS. *See* near-infrared spectroscopy
 nitrous oxide, 75, 183
 NMS. *See* neuromuscular scoliosis
 nociceptive pain, 249
 non-MH triggering anesthetics, 65–6
 non-polarizing muscle relaxants, 66
 nonsteroidal anti-inflammatory drugs (NSAIDs), 250
 arachidonic acid pathways, 250
 for asthma, 49
 for chronic pain, 258
 with OSA, 138–9
 PONV and, 24
 normovolemic hemodilution, 44
 NSAIDs. *See* nonsteroidal anti-inflammatory drugs
 NTD. *See* open neural tube defects
 nusinersen, 68
 Nuss procedures, 208–10
 anesthetic concerns, 209
 common analgesic agents, 209–10
 complications from, 209–10
 indications for, 208
 removal of, 210
 obstructive sleep apnea (OSA), 65, 137.
 See also adenoidectomy;
 tonsillectomy
 diagnosis of, 137
 inhalation induction and, 138
 pain management plans with, 138–9
 NSAIDs in, 138–9
 prevalence rates, 137
 severity of, 137
 McGill Oximetry Scoring System, 137–8
 scales for, 138
 sleep disordered breathing compared to, 137
 induction plans and, 138
 tonsillectomy indications and, 137–8
 OCR. *See* oculocardiac reflex
 oculocardiac reflex (OCR), 181–2
 omphalocele, in neonates, 6–9
 abdominal compartment syndrome and, 7
 anesthetic considerations for, 8
 risks as part of, 8
 RSI in, 8
 characteristics of, 6
 diagnostic evaluations for, 8–9
 gastroschisis compared to
 characteristic differences in, 7
 pathophysiological differences, 6
 laboratory evaluations for, 8–9
 management of, 6
 preoperative evaluations for, 8–9
 prevalence rates for, 6
 primary abdominal wall closure, 7–8
 prognosis for, 9
 silo treatment for, 7
 staged abdominal wall closure, 7–8
 before surgery, 6–7
 ondansetron, 182–3
 open neural tube defects (NTD), 197–200
 anomalies associated with, 197
 causes of, 197
 clinical definition of, 197
 incidence rates, 197
 physiologic effects, 197
 pre-anesthetic evaluation of, 198
 prenatal repair of, 198–200
 anesthetic considerations for, 199
 fotoscopic approach, 199
 MOMS, 198–9
 perioperative considerations, 199–200
 in second trimester, 199–200
 public health interventions, 198
 surgical options for, 198
 open thoracotomy, 104
 opioids, 186–7
 OSA. *See* obstructive sleep apnea
 PAED scale. *See* Pediatric Anesthesia Emergence Delirium scale
 pain catastrophizing, 256–7
 pain management. *See also* distraction techniques; postoperative pain management
 with bladder exstrophy, 191–2

- IASP guidelines, 254–5
 with OSA, 138–9
 NSAIDs in, 138–9
 with pediatric burns, 75
 analgesic options, 75
 sedative options, 75
 with pediatric trauma, 80
 regional anesthesia for, 250
 after thoracic surgery, 105–6
 palpation, 34
 PAPVR. *See* partial anomalous pulmonary venous return
 paralysis, cystic fibrosis and, 62
 paravertebral nerve block, 239–42
 paravertebral space, 239
 parental catastrophizing, 257
 parents
 neuroapoptosis and, notifications about, 17–18
 preoperative anxiety and
 benefits and risks of parental presence, 20–1
 informed consent by, 20
 preparation for, 20
 partial anomalous pulmonary venous return (PAPVR), 305
 anesthetic concerns with, 305
 partial thickness burns, 70–1
 patent ductus arteriosus (PDA), 36
 age of presentation, 269–70
 anatomic location, 269–70
 closure of, 270–1
 indications for, 270–1
 invasive approaches, 270–1
 postoperative considerations for, 271–2
 common medical therapies, 270
 diagnosis of, 269
 endocarditis prophylaxis and, 271–2
 hemodynamic consequences, 270
 incidence rates, 269
 ligation procedures, 271
 open surgical technique, 271
 pathophysiology, 269–70
 in post-natal life, 271–2
 symptoms of, 269
 TGA and, 296
 VATS and, 271
 patient-controlled analgesics (PCAs), 5, 252
 PDA. *See* patent ductus arteriosus
 PDNV. *See* postoperative discharge nausea and vomiting
 pectoralis truncal block, 243–4
 pectus excavatum
 clinical definition, 208
 Haller index, 208–9
 Nuss procedures, 208–10
 anesthetic concerns, 209
 common analgesic agents, 209–10
 complications from, 209–10
 indications for, 208
 removal of, 210
 pediatric anesthesia
 analgesics used in, 3
 patient-controlled, 5
 annual procedure rates, 16
 antibiotics used in, 4
 blood products used in, 2–4
 cardiovascular drug dosing in, 4–5
 commonly used drugs in, 3–4
 Factor concentrates used in, 2–4
 minimum alveolar concentration of
 anesthetic agents, 2–3
 neurological surgery dosages in, 4
 normal blood pressure values, for
 children, 1
 normal blood volume values, for
 children, 1–2
 normal equipment sizes, for
 children, 2
 normal heart rate values, for
 children, 1
 normal respiratory rates, for
 children, 1
 perioperative guidelines, 2
 Pediatric Anesthesia Emergence
 Delirium (PAED) scale, 27
 Pediatric End-Stage Liver Disease
 (PELD) score, 122
 pediatric fear-avoidance (p-FA) model,
 257
 pediatric trauma. *See* trauma
 PELD score. *See* Pediatric End-Stage
 Liver Disease score
 penile procedures, anesthesia for
 alternative types of, 188
 caudal epidural space, anatomy of,
 184
 for circumcision, 184. *See also* caudal
 blocks
 peripheral nerve blocks, 187
 caudal blocks compared to, 187–8
 sacral hiatus, anatomy of, 184
 for sensory innervation of the penis,
 184
 percent predicted lung volume (PPLV),
 101
 perioperative patient management,
 38–40. *See also* transfusions
 for bleeding disorders, 38–40. *See
 also specific disorders*
 blood loss minimization measures,
 44
 cell saver, 44
 with erythropoietin, 44
 preoperative autologous blood
 donation, 44
 blood recovery in, 44
 blood reinfusion in, 44
 controlled hypotension and, 44
 cryoprecipitate indications, 41
 hemophilia and, 39–40
 heparin resistance in, 41
 SCD and, 38
 oxyhemoglobin dissociation curve,
 39
 thalassemia and, 38
 vWD and, 38–9
 peripheral nerve blocks, 187
 caudal blocks compared to,
 187–8
 Perlman syndrome, 111
 persistent fetal circulation, 266–7
 persistent transitional circulation,
 267
 p-FA model. *See* pediatric fear-
 avoidance model
 phenylephrine, 200
 phrenic nerve blocks, 218
 PIS. *See* propofol infusion syndrome
 plasma midazolam, 21
 platelet function, hydroxyethyl starch
 in, 41
 PONV. *See* postoperative nausea and
 vomiting
 portopulmonary hypertension
 (PPHN), 120
 posterior abdominal wall, 236, 238.
 See also truncal blocks
 thoracolumbar fascia, 236–7
 posterior fossa tumor, 158–60
 surgical positioning for, 159
 syndromes associated with,
 159–60
 VAE in, 159–60
 postoperative apnea, 31
 postoperative discharge nausea and
 vomiting (PDNV), 24
 antiemetic administration, 11
 incidence rates for, 25
 prediction of, 25
 risk factors for, 25
 postoperative nausea and vomiting
 (PONV)
 anesthetic factors for, 24
 antiemetic administration, 11
 clinical presentation of, 24
 CTZ and, 24
 incidence rates of, 24
 over three years of age, 24
 multimodal model, 24
 NSAIDs and, 24
 risk factors for, 24
 after strabismus surgery, 182–3

- postoperative nausea and vomiting (PONV) (cont.)
 anesthetic techniques for
 prevention of, 182–3
 intraoperative prevention
 strategies, 182–3
 tiered model, 24
 treatment of, 25
- postoperative pain management, acute.
 See also distraction techniques
 assessment strategies, for children,
 251
 classification of, 249
 with cognitive impairment, 251–2
 checklists and scales for, 252
 common side effects, 252
 with congenital heart disease,
 252–3
 of dysfunctional pain, 249–50
 of inflammatory pain, 249–50
 of neuropathic pain, 249–50
 of nociceptive pain, 249
 non-opioid strategies, 250–1
 with opiate-based analgesics, dosing
 guidelines for, 251
 pain mechanisms, 249–50
 with PCAs, 252
 suboptimal treatment in, 251
 after surgery, 253
- postoperative pain management, IASP
 guidelines, 254–5
- postoperative tonsillar bleeding, 140
- PPHN. *See* portopulmonary
 hypertension
- PPLV. *See* percent predicted lung
 volume
- premature infants
 BSA for, 30
 cardiovascular issues in, 28
 apnea of maturity, 28
 BPD, 28–9
 pulmonary hypertension, 28
 cerebral palsy, 29–30
 classification of, 30
 consequences of, 30
 incidence rates of, 30
 common medical issues for, 28–9
 general anesthesia for, 31
 postoperative apnea from, 31
 gestational age and weight
 classifications for, 29
 hypoglycemia in, 30
 hypothermia for, 30
 IVH, 28–9
 grading of, 29–30
 pathophysiology of, 29
 NEC, 31
 neonatal acidosis, 31
 preoperative evaluation for, 31
 anesthesia preferences in, 31
 neonatal spinal anesthetic in, 31
 regional anesthesia for, 31
 postoperative apnea from, 31
 ROP, 29
 transfusions for, 40
 preoperative anxiety
 behavioral interventions for, 20
 efficacy of, 20
 incidence rates for, 19
 parental presence and
 anxiety for parents, preparation
 for, 20
 benefits and risks of, 20–1
 informed consent, 20
 pharmacological interventions for, 20
 premedications for
 clonidine, 22
 dexmedetomidine, 20
 diazepam, 22
 ketamine, 22–3
 midazolam, 20–2
 reduction strategies, benefits of,
 19–20
 risk factors for, 19
 separation anxiety, 19
 preoperative autologous blood
 donation, 44
 pressor refractory septic shock, 52
 primary abdominal wall closure,
 7–8
 primum ASDs, 278–9
 promethazine, 182
 propofol, 182–3, 205, 248, 314
 propofol infusion syndrome (PIS), 55
 prostaglandin E1, 274
 protein losing enteropathy, 317
 PS. *See* pyloric stenosis
 psychosocial model of pain, 257
 PT coagulation studies, 42
 pulmonary artery catheters, 36
 pulmonary hypertension, 286
 anesthetic considerations for, 314
 causes of, 310
 with CDH, 102
 clinical investigation of, 311
 clinical presentation of, 310
 diagnosis of, 312
 imaging of, 311–12
 incidence rates of, 310
 pathophysiology of, 310–11
 in premature infants, 28
 treatment of, 312–13
 target pathways in, 313–14
 pulmonary hypertensive crisis, 311
 treatment of, 314
 pulmonary stenosis, 297
 pulmonary venous obstruction (PVO),
 304
- pulse oximetry
 fetal hemoglobin and, 36
 hyperbilirubinemia and, 36
 NIRS compared to, 33
 sources of error in, 36
- PVO. *See* pulmonary venous
 obstruction
- pyloric stenosis (PS)
 age of presentation, 96–7
 clinical presentation, 96
 diagnosis of, 96–7
 genetic components of, 96–7
 historical overview of, 96
 incidence rates for, 96–7
 postoperative considerations, 98
 preoperative evaluation, 97–8
 bicarbonate correction in, 98
 dehydration assessment, 98
 fluid resuscitation goals, 98
 intubation preferences, 98
 metabolic profile, 98
 patient workup, 97–8
 after pyloromyotomy, 97
 risk factors for, 97
 pyloromyotomy, 97
- QL block. *See* quadratus lumborum
 block
- Qp:Qs ratio, 283–4, 288–9
- quadratus lumborum (QL) block, 241–3
 TAP block compared to, 242
- radiation burns, 70
- raised intracranial pressure (ICP), 155
- rapid sequence intubation (RSI), 8
- re-coarctation, 275–6
- rectus sheath, 236
- rectus sheath block, 238–40
- regional anesthesia
 for CPSP, 257–8
 for EA/TEF, 95
 for inguinal hernia, 81
 lower extremity nerve blocks, 225–6,
 230–1
 for pain management, 250
 with pediatric trauma, 80
 for premature infants, 31
 postoperative apnea from, 31
- remifentanyl, 205
- renal function. *See also specific
 disorders*
 with Beckwith-Wiedemann
 syndrome, 9
 in neonates, adult functions
 compared to, 11–12
 with severe sepsis, 54
- renal transplantation. *See also* end-
 stage renal disease
 age distribution for, 129

- anesthesia induction in, 131
 CKD, 128
 classification stages of, 128–9
 clinical definition, 128
 eligibility assessment for
 transplantation, 128
 contraindications to, 130
 DDKT, 130
 hypotension during ureteral re-
 implantation, 132
 intra-operative management,
 131–2
 analgesic options, 131
 fluid management, 131–2
 kidney reperfusion with, 132
 monitors in, 130–1
 perioperative immunosuppression
 with, 132–3
 preoperative workup, 130
 for hypertension, 130
 imaging studies, 130
 laboratory workup, 130
 volume maintenance in, 130
 transfusion goals, 130
 respiratory failure, for pediatric burns,
 72
 respiratory rates, for children, 1
 retinopathy of prematurity (ROP), 29
 rigid bronchoscopy, 90
 rocuronium, 147
 ROP. *See* retinopathy of prematurity
 ropivacaine, 192, 215
 rotational thromboelastogram
 (ROTEM), 42
 RSI. *See* rapid sequence intubation
- sacral dimples, 185–6
 sacral hiatus, anatomy of, 184
 sacral plexus nerve blocks, 225–8
 Saethre-Chotzen syndrome, 174–7
 SBE prophylaxis. *See* subacute bacterial
 endocarditis prophylaxis
 SCD. *See* sickle cell disease
 sciatic nerve block, 232–3
 imaging of, 232–3
 scoliosis surgery
 anesthetic management, 205
 common anesthetics, 205
 neurological signal loss and, 205
 cardiopulmonary status and, 203
 prone positioning as influence on,
 205–6
 Cobb angle and, 202–3
 comorbidities with, 202
 controlled hypotension during,
 204–5
 intraoperative considerations, 203–6
 anesthetic implications, 203–4
 monitoring as part of, 204
 pharmacologic adjuncts, 206
 vascular access, 204
 IS, 202
 blood loss with, 204
 NMS, 202
 blood loss with, 204
 postoperative considerations, 206–7
 preoperative considerations, 203–6
 prone positioning during, 205–6
 cardiopulmonary status, 205–6
 risk factors from, 206
 second degree burns. *See* partial
 thickness burns
 secundum ASDs, 277–8, 280
 seizures, from epilepsy, 161
 selective serotonin norepinephrine
 reuptake inhibitor (SNRI), 251
 sensory innervation of the penis, 184
 separation anxiety, 19
 sepsis
 age of presentation for, 51–2
 anesthetic considerations for, 54–5
 ARDS and, 54
 ventilator strategy for, 54
 arterial lines for, 52
 central venous lines for, 52–3
 clinical definition, 50
 common infection sites, 51
 diagnostic criteria, 51
 incidence rates, 51–2
 monitoring devices for, 53
 PIS and, 55
 severe, 50, 54
 common pathogens in, 51
 disseminated intravascular
 coagulation from, 54
 renal dysfunction from, 54
 thrombocytopenia and, 54
 SIRS, 50
 vital signs for, by age, 50–1
 septal defects. *See* atrial septal defects;
 ventricular septal defects
 septic shock, 50, 52
 epinephrine treatment, 52
 hemodynamic consequences of, 52
 milrinone treatment for, 52
 MODS, 50, 53–4
 sequential organ failure
 assessment, 53–4
 pathophysiology of, 52
 pressor refractory, 52
 surgical procedures with, 53
 postoperative considerations for,
 55
 severe sepsis, 50, 54
 common pathogens in, 51
 disseminated intravascular
 coagulation from, 54
 renal dysfunction from, 54
 thrombocytopenia and, 54
 shunts. *See* cerebral spinal fluid
 sickle cell disease (SCD), perioperative
 patient management and, 38
 simple craniosynostosis, 173–7
 single ventricle palliation, 329
 sinus venosus ASDs, 278, 280
 SIRS. *See* systemic inflammatory
 response syndrome
 sleep disordered breathing
 induction plans and, 138
 OSA compared to, 137
 tonsillectomy indications and, 137–8
 SMA. *See* spinal muscular atrophy
 SMN gene. *See* survival motor neuron
 gene
 SNRI. *See* selective serotonin
 norepinephrine reuptake
 inhibitor
 Sotos syndrome, 111
 spina bifida, 152. *See also*
 myelomeningocele
 maternal folate deficiency, 152
 predisposing risk factors, 152
 prenatal studies, 152
 types of, 152
 spinal anesthesia, for inguinal hernia,
 in infants, 82–4
 cardiorespiratory effects, 83–4
 patient management in, 83
 preoperative application of, 83
 spinal muscular atrophy (SMA)
 anesthetic considerations, 68–9
 induction and maintenance of, 69
 clinical definition of, 68
 juvenile, 68
 nusinersen and, 68
 SMN gene and, 68
 types of, 68
 Werdnig-Hoffmann, 68
 Wohlfart-Kugelberg-Welander
 syndrome, 68
 spring-assisted cranioplasty, 175
 staged abdominal wall closure, 7–8
 strabismus, surgical repair for
 amblyopia, 180
 associated syndromes, 180
 clinical definition of, 180
 emergence delirium after, 183
 extubation after, 182
 malignant hyperthermia risk, 181
 masseter muscle spasm, 181
 OCR risks, 181–2
 PONV after, 182–3
 anesthetic techniques for
 prevention of, 182–3
 intraoperative prevention
 strategies, 182–3
 preoperative assessment, 180–2

- strabismus, surgical repair for (cont.)
 airway assessment, 181
 anesthetic maintenance, 181
 FDT, 181
 subacute bacterial endocarditis (SBE)
 prophylaxis, 331
 subglottic stenosis
 acquired, 144
 airway size determination, 145
 clinical definition, 144–7
 congenital, 144
 cricoid cartilage and, 145
 examination and workup for, 145–6
 Myer-Cotton grading scale, 144–6
 presurgical planning, 145
 symptoms of, 144
 treatment strategies for, 145–7
 mild stenosis, 145
 severe stenosis, 145–7
 vocal chords and, 145
 succinylcholine, 66, 73
 sufentanil, 205
 suffocation. *See* accidental suffocation
 sugammadex therapy, 62
 superficial burns, 70
 superior cavopulmonary anastomosis (SCPA), 328–30
 age for performance of, 329
 anesthetic risks, 330
 discharging a patient with, 332–3
 hematocrit with, 328–9
 hemoglobin-oxygen saturation with, 328–9
 induction methods for, 331
 invasive line considerations, 332
 laparoscopic surgery, 332
 maintenance of anesthesia, 332
 patient selection for, surgical assessment with, 330
 physiologic advantage of, 329
 preoperative evaluation of, 330
 respiratory considerations for, 331–2
 laryngeal mask airway, 332
 TCPA compared to, 329–30
 superior vena cava, 264
 LSVC, 279
 SVC syndrome, 89
 supraclavicular brachial plexus block, 218–20
 survival motor neuron (SMN) gene, 68
 SVC syndrome. *See* superior vena cava
 syndrome of inappropriate antidiuretic hormone, 159–60
 systemic inflammatory response syndrome (SIRS), 50
 vital signs for, by age, 50–1
 TACO. *See* transfusion-associated circulatory overload
 TAP block. *See* transversus abdominis plane block
 TAPVR. *See* total anomalous pulmonary venous return
 TCA. *See* tricyclic antidepressants
 TCPA. *See* total cavopulmonary anastomosis
 TEE. *See* transesophageal echocardiogram
 TEF. *See* tracheoesophageal fistula
 TEG. *See* thromboelastography
 temperature monitoring, 36
 with muscular dystrophy, 65–6
 with pediatric burns, 73
 with pediatric trauma, 79
 hypothermia issues, 79
 temporary VAD, 321
 tetralogy of Fallot (ToF)
 anatomy of, 290–1
 spectrum of, 291–2
 artificial conduits, 294–5
 clinical definition, 290
 exam findings, 292
 JET and, 294
 management of, 292–3
 medications in, 293
 Melody valve and, 295
 surgical repair of, 293–4
 complications from, 293–4
 transcatheter pulmonary valve and, 294–5
 TGA. *See* transposition of the great arteries
 thalassemia, 38
 thermal burns, 70
 third degree burns. *See* full thickness burns
 third space fluid loss, 110
 thoracic insufficiency syndrome, 211–12
 associated conditions with, 211–12
 clinical definition, 211
 imaging studies, 211–12
 thoracic surgery
 congenital lung malformations, 11
 bronchopulmonary sequestration, 106
 CLE, 106
 CPAM, 106
 for lung masses, 104
 management strategies, for neonates, 106–7
 open thoracotomy, 104
 postoperative pain management, 105–6
 preoperative considerations, prior to lung tumor resection, 104
 single lung isolation in, 104–5
 hypoxemia risks, 105
 VATS, 104
 thoracolumbar fascia, 236–7
 thrombocytopenia, 54
 thromboelastography (TEG), 42–3
 thyroid storm, 151
 causes of, 151
 treatment for, 151
 thyroid surgery
 airway evaluation, 149
 postoperative obstructions, 150
 cardiac evaluation, 149
 Graves' disease and, 149
 laryngeal nerve injuries, 150
 NIM tube, 149–50
 preoperative lab studies, 149–50
 tirofiban, 43–4
 TLS. *See* tumor lysis syndrome
 tobramycin therapy, 62
 ToF. *See* tetralogy of Fallot
 tonsillectomy
 complications after, 139–40
 anxiety as, 140
 with breathing, 140
 postoperative tonsillar bleeding, 140
 indications for, 137–8
 OSA and, 137–8
 postoperative plans, 139–40
 length of hospitalization, 139
 total anomalous pulmonary venous return (TAPVR)
 anatomic variants of, 302–3
 anesthetic concerns with, 305
 anomalies associated with, 303
 clinical presentations of, 303–4
 diagnosis of, 302, 304
 natural history of, 304
 neonates with, 304–5
 long-term outcome of, 305
 short-term outcome of, 304
 PAPVR compared to, 305
 pulse oximetry screening, 302
 PVO, 304
 signs and symptoms, 302
 total cavopulmonary anastomosis (TCPA), 329–30
 SCPA compared to, 329–30
 single ventricle palliation, 329
 tracheal cross-sectional area studies, 88
 tracheoesophageal fistula (TEF), 92.
 See also VACTERL/VATER syndrome
 age of presentation, 92
 bronchoscopy for, 94

- cardiac defects with, 93
- continuous gastric insufflation, 95
- ETT positioning, 94
- fistula variants, 92–3
- incidence rates, 92
- induction methods for, 94
- intraoperative approach to, 95
- mortality expectations with, 94
- postoperative approach to, 95
- preoperative evaluations with, 94
- regional anesthetics for, 95
- tracheostomy. *See* emergency tracheostomy
- TRALI. *See* transfusion-related acute lung injury
- tranexamic acid, 44
- transcatheter pulmonary valve, 294–5
- transesophageal echocardiogram (TEE), 36
- transfusion-associated circulatory overload (TACO), 40–1
- transfusion-related acute lung injury (TRALI), 40–1
 - diagnosis of, 43–4
 - meizothrombin, 43–4
 - tirofiban, 43–4
- transfusion-related
 - immunomodulation (TRIM), 40–1
- transfusions, blood, 40
 - ABO compatibility, 41
 - antifibrinolytics with, 44
 - blood volume estimates, 40
 - for burn debridement blood loss, 74
 - clotting factors, 41
 - component therapy in, 41
 - craniosynostosis and, 176–7
 - platelet ratios, 176–7
 - reduction strategies, 177
 - of FFP, 40–1
 - guidance tests for, 42–3
 - with activated protein C, 43
 - aPTT coagulation studies, 42
 - FiBTEM, 42–3
 - PT coagulation studies, 42
 - ROTEM, 42
 - TEG, 42–3
 - hematopoietic stem cell transplantation, 42
 - hydroxyethyl starch, in platelet function, 41
 - major trauma implications for, 40
 - MBT, 41–2
 - normovolemic hemodilution, 44
 - for premature infants, 40
 - renal transplantation and, 130
 - TACO, 40–1
 - TRALI, 40–1
 - diagnosis of, 43–4
 - meizothrombin, 43–4
 - tirofiban, 43–4
 - whole blood, 41
- transitional circulation, 265–6. *See also* fetal circulation
 - persistent, 267
- transposition of the great arteries (TGA)
 - after arterial switch operation, 301
 - atrial septum and, 296
 - balloon trial septostomy for, 298
 - cardiopulmonary bypass for, 300
 - circulation physiology with, 297
 - clinical definition of, 296
 - coexisting anomalies with, 296–7
 - diagnosis of, 297
 - D-TGA, 296
 - arterial blood gas in, 297–8
 - echocardiogram data, 298
 - illustration of, 297
 - intraoperative considerations, 299–300
 - intraoperative transesophageal echocardiography, 300
 - L-TGA, 296
 - medical ventilation for, 298
 - monitoring of, 299
 - in neonates, 297–8
 - anesthetic considerations, 299
 - palliative procedures for, 299
 - surgical options for, 298–9
 - oxygen saturation in, 296
 - PDA and, 296
 - perioperative mortality, 299
 - postoperative concerns, 300
 - prostaglandin administration, 298
 - pulmonary stenosis with, 297
- transversus abdominis plane (TAP) block, 238–9
 - QL block compared to, 242
- trauma, pediatric
 - through accidental suffocation, 76
 - ACS verification process, 76
 - airway assessment with, 78
 - components of, 78
 - in primary survey approach, 76–7
 - anesthetic implications with, 79–80
 - cervical spine injury, 79
 - in intraoperative management, 79
 - in postoperative management, 79–80
 - with regional anesthesia, 80
 - classification of, 76
 - demographics of, 76
 - evaluation of, 76
 - GCS for, 77
 - injury mechanisms, 78
 - organization of care, 76
- pain management, 80
- primary survey approach, 76–7
 - of airway, 76–7
 - of breathing, 77
 - of circulation, 77
 - of disability, 77
 - through exposure, 77
- secondary survey approach, 77–8
- temperature management, 79
 - hypothermia issues, 79
- vascular assessment
 - access issues in, 78–9
 - intraosseous lines, 78–9
 - in primary survey approach, 77
- tricyclic antidepressants (TCAs), 251
- TRIM. *See* transfusion-related immunomodulation
- truncal blocks, 237–44
 - complications with, 243
 - erector spinae block, 243
 - ilioinguinal-iliohypogastric block, 238–41
 - paravertebral nerve block, 239–42
 - pectoralis, 243–4
 - QL block, 241–3
 - TAP block compared to, 242
 - recommended dosage for, 243
 - rectus sheath block, 238–40
 - TAP block, 238–9
 - QL block compared to, 242
- truncus arteriosus
 - anesthetic management with, 308–9
 - classification of, 306–7
 - clinical definition, 306
 - congenital heart defects and, 307
 - embryological basis of, 307
 - genetic abnormalities for, 307
 - natural history of, 308
 - pathophysiology of, 307–8
 - postoperative concerns with, 309
 - sequelae of, 309
 - signs and symptoms, 307
 - surgical approach to, 308–9
 - infection precautions, 308
 - pre-anesthetic concerns for, 308
- tumor lysis syndrome (TLS), 91
- tumors. *See* embryonal tumors; neurological tumors; Wilms tumor
- Turner syndrome, 273
 - cardiac issues with, 273
- 22q11 deletion syndrome, 144
- ultrasound, 186. *See also* truncal blocks
 - axillary nerve block, 222–3
 - with infraclavicular block, 220–1
 - of lower extremity nerve blocks, adductor canal block, 231–2
- umbilical catheters, 34

- uncontrolled pain, 260
- unrepaired ASDs, 279
 - natural history of, 280
- upper extremity nerve blocks. *See also*
 - infraclavicular block;
 - interscalene brachial plexus nerve block
- axillary nerve block, 223
 - ultrasound imaging, 222–3
- supraclavicular brachial plexus block, 218–20
- upper respiratory infections (URIs)
 - Glenn procedures and, 331
 - with myringotomy and ear tube placement, 134
 - anesthetic management with, 134
 - hypoxemia and, 134
 - timing of elective procedures, 135–6
- ureteral re-implantation, 132
- URIs. *See* upper respiratory infections
- VACTERL/VATER syndrome, 92–4
 - anal defects in, 93
 - classic limb defects in, 93–4
 - neurocognitive function in, 93–4
 - renal defects in, 93–4
 - vertebral defects in, 93
- VAD. *See* ventricular assist devices
- VAE. *See* venous air embolism
- vagal nerve stimulator, 161
- VATS. *See* video-assisted thoracoscopic surgery
- velopharyngeal insufficiency (VPI), 170
- venous air embolism (VAE), 159–60
 - craniosynostosis and, 176
- ventricular assist devices (VAD)
 - blood pressure targets with, 325
 - chest compressions with, 325
 - defibrillation with, 325
 - device placement for, timing of, 321
 - ECMO compared to, 320–1
 - indications for, 320
 - induction regimens, 325
 - long-term, 321
 - maintenance regimens, 325
 - monitors in, 324–5
 - non-cardiac procedures with, 321–2
 - parameters of, assessment of, 323–4
 - perioperative management of, 326–7
 - physiologic principles for, 324
 - preoperative assessment, 322–3
 - selection criteria for, 321–2
 - temporary, 321
- ventricular septal defects (VSD)
 - age of presentation, 282
 - cardiac catheterization for, 284
 - characteristic murmur with, 285
 - clinical presentation of, 283
 - closure of, 284
 - conotruncal, 284
 - coventricular, 284
 - incidence of, 282
 - inlet, 284
 - muscular, 284–5
 - natural history of, 282
 - pathophysiology of, 285
 - Qp:Qs ratio with, 283–4
 - surgical approaches to, 285
 - types of, 282–3
 - unrepaired, 284
- hemodynamic consequences of, 285
- ventricular septum, 282
- vertical expandable prosthetic titanium rib (VEPTR) procedure, 212–13
 - indications for, 212
 - medical assessment for, 213
 - postoperative concerns, 213
 - surgical complications from, 212
- video-assisted thoracoscopic surgery (VATS), 104, 271
- vincristine, 109
- visible icterus, evaluation of, 10
- vocal chords, 145
- von Willebrand disease (vWD), 38–9
- VPI. *See* velopharyngeal insufficiency
- VSD. *See* ventricular septal defects
- vWD. *See* von Willebrand disease
- Watcha scale, for ED, 27
- Werdnig-Hoffmann SMA, 68
- whole blood transfusions, 41
- Wilms tumor
 - anesthetic management, 111
 - inducing anesthesia, 112
 - intra-cardiac extension of tumor, 111–12
 - congenital syndromes with, 111
 - diagnosis of, 108, 111
 - differential, 111
 - epidemiology of, 111
 - incidence rates of, 111
 - postoperative analgesia, 112
- Wohlfart-Kugelberg-Welander syndrome, 68